CASI Pharmaceuticals Inc CASI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CASI is a good fit for your portfolio.
News
-
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
-
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
-
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
-
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
-
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
Trading Information
- Previous Close Price
- $2.24
- Day Range
- $2.14–2.36
- 52-Week Range
- $1.85–8.48
- Bid/Ask
- $2.25 / $2.52
- Market Cap
- $30.02 Mil
- Volume/Avg
- 90,570 / 222,822
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.89%
Company Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 243
Competitors
Valuation
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Price/Earnings (Normalized) | — | 13.96 |
Price/Book Value | 1.30 | 1.63 |
Price/Sales | 0.92 | 2.48 |
Price/Cash Flow | — | 13.33 |
Price/Earnings
CASI
PFE
Financial Strength
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Quick Ratio | 2.45 | 0.58 |
Current Ratio | 3.55 | 0.91 |
Interest Coverage | — | 0.74 |
Quick Ratio
CASI
PFE
Profitability
|
Metric
|
CASI
|
PFE
|
|---|---|---|
Return on Assets (Normalized) | −19.38% | 4.98% |
Return on Equity (Normalized) | −47.15% | 10.90% |
Return on Invested Capital (Normalized) | −29.59% | 7.28% |
Return on Assets
CASI
PFE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Thdcssdwq | Lsj | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mwtjlphp | Mdsmy | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rpsdyzgkp | Wzkbg | $98.9 Bil | |
MRNA
| Moderna Inc | Zqyfzrf | Xkmr | $39.7 Bil | |
ARGX
| argenx SE ADR | Tmmrydzh | Mklg | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Qjtscyrsw | Bbvm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xmbfmlyds | Bmyphl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wfbfwmpzb | Wqzwvp | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Brwrfzgxv | Phknw | $12.3 Bil | |
INCY
| Incyte Corp | Srxxqrrr | Kfvypt | $11.8 Bil |